HONG KONG and SHANGHAI, Oct. 3, 2018 /PRNewswire/ — China’s leading one-stop healthcare ecosystem platform, Ping An Good Doctor (the “Company”, stock code: 1833.HK), today announced the strategic partnership with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (“CR Sanjiu”). The two parties will integrate their respective superior resources, such as Ping An Good Doctor’s leading AI healthcare technologies and massive user scale, and CR Sanjiu’s product advantages in over-the-counter (OTC) and prescription drugs, to build the emerging business model of “Internet + Medical” together. The collaboration will not only enhance the medical services of both companies, but also bring a deep integration of the mobile internet and medical services to the industry.

CR Sanjiu is a large state-owned pharmaceutical listed company that mainly engages in the research and development, production, sales of pharmaceutical products and related healthcare services. Its main businesses are OTC and Chinese medicine prescription drugs. In terms of OTC core products, CR Sanjiu maintains leading market shares in the products of cold medicine, gastroenterology, dermatology, pediatrics, cough medicine and orthopedic medicine. Its Chinese medicine prescription drugs also have a strong presence in the Chinese market, including Chinese medicine formula granules, cardiovascular and cerebrovascular medicine, anti-tumor medicine, anti-infective medicine, etc. CR Sanjiu’s flagship brands include “999”, Xue Sai Tong Soft Capsules, Shunfeng and Tianhe, which are highly reputable and influential in the Chinese pharmaceutical industry.

Ping An Good Doctor is a leading one-stop healthcare ecosystem platform in China. Leveraging the world’s leading AI healthcare technologies, the Company consolidates its in-house medical team of more than a thousand medical professionals, external contracted doctors and offline healthcare network, to establish a self-contained servicing system that allows its users to consult doctors and purchase medicine online, or consult doctors online and receive medical treatment offline. Ping An Good Doctor now works with approximately 3,100 hospitals (including more than 1,200 Class III Grade A hospitals), and more than 2,000 healthcare institutions such as physical examination centers, dental clinics, cosmetic surgery institutions and more than 10,000 pharmacy outlets.

In China, the “Healthy China” plan has become the national strategy, and “Internet + Medical” is emerging as an important part of China’s Healthcare Reform. The integration of internet medical and traditional medical entities has become one of the development trends of the medical industry. The strategic cooperation between Ping An Good Doctor and CR Sanjiu reflects this trend. They will consolidate their respective resources on pharmaceutical new retail, Chinese medicine revitalization, medical AI, family doctor services, marketing and poverty alleviation programs.

In terms of pharmaceutical new retail, the two companies will leverage on Ping An Good Doctor’s internet hospital, in-house medical team and substantial user traffic, as well as CR Sanjiu’s advantages in product and brand, to strengthen the self-contained servicing chain. From doctor consultations, prescriptions, product purchases to drug delivery, the comprehensive healthcare service will provide a better experience for its users. For the revitalization of Chinese medicine, the two parties will focus on online Chinese medicine healthcare. They will also use Ping An Good Doctor’s big data and user’s profiling to explore new models of “internet + Chinese medicine healthcare” and “internet + chronic illness management”, striving to promote the standardization of Chinese medicine and expand the client base of the Chinese medicine market. In addition, the two parties will collaborate to strengthen marketing programs, promoting each other’s brand online and offline, and to expand the client base and enhance user loyalty.

About Ping An Good Doctor (01833.HK)

Ping An Good Doctor is the leading one-stop healthcare ecosystem platform in China. By combining “mobile health + AI technology”, the Company strives to provide every family with a family doctor, every person with an e-health profile and everyone with a healthcare management plan. Ping An Good Doctor has established a comprehensive, one-stop healthcare ecosystem covering family doctor services, consumer healthcare services, a health mall as well as health management and wellness interaction.

As of the end of June 2018, there were 228 million registered users and the Company’s MAU reached 48.6 million. Ping An Good Doctor is today the largest mobile medical application in China in terms of user scale. Ping An Good Doctor employs more than a thousand medical personnel (Assistant Supervisor Level or above from Class III Grade A Hospitals) in its in-house medical team and contracts with 4,650 renowned external doctors. This in-house medical team, empowered by our proprietary AI technology, provides users with 24 x 7 online consultation services. In our offline partnership network, Ping An Good Doctor collaborates with approximately 3,100 hospitals (including more than 1,200 Class III Grade A hospitals) to provide services such as hospital referral, appointment and inpatient arrangements. Ping An Good Doctor also partners with more than 2,000 healthcare institutions, including physical examination centers, dental clinics, cosmetic surgery institutions and more than 10,000 pharmacy outlets, to provide relevant health and wellness services to our users. By integrating our AI-empowered medical team, external doctors and offline network, Ping An Good Doctor has established a closed-loop healthcare ecosystem which enables our users to enjoy online consultations and online drug purchases, as well as online consultations and offline follow-up treatment, thereby providing convenient, high-quality and efficient family doctor services.

In April 2015, the App “Ping An Good Doctor” was officially launched. In May 2016, the Company completed an A round financing and raised US$500 million. In December 2017, the Company completed the pre-IPO financing from Softbank Vision Fund, during which it raised US$400 million. On 4 May 2018, Ping An Good Doctor became the No.1 listed internet health-tech company in the world when it joined the Hong Kong Stock Exchange, stock code 01833.HK. Our IPO cornerstone investors include Blackrock, Capital Group, GIC, Canada Pension Plan Investment Board, Khazanah Nasional Berhad, Swiss Re and CP Group.

Photo – https://photos.prnasia.com/prnh/20181003/2256229-1

MOSCOW, Oct. 8, 2018 /PRNewswire/ — Kinetic Step’s Russian military engineer has invented a biomechanical exoskeleton which provides an easy method of travelling, based on the principle of physical pendulum movement. Whilst developing KineticStep, the key task was to give individuals a chance to walk as easily and efficiently as wheel rolls. This would provide consumers with the opportunity to walk 2-3 times further than their usual walking distance, to maintain a fulfilling, active lifestyle. The Kinetic Step exoskeleton has been specially designed to enable individuals to walk great distances and carry heavy loads with almost no effort.

To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/8412651-kineticstep-first-biomechanical-exoskeleton/

Despite this, having solved the main biomechanics problem (optimised transportation of the general center of an individual’s mass), the design based on pendulum mechanism interaction also revealed a number of positive effects applicable in medicine. Kinetic Step also aims to compensate for less abled consumers’ lost functionality, to increase strength, and to expand an individual’s range of movement through the use of external frames and actuators. The ability to walk without joint stress promises the possibility of exoskeleton-efficient use in cases of knee joint injuries or diseases. Through this, it will be able to give anyone and everyone the opportunity and ability to walk with relaxed legs, without bending their knees, and maintain a healthy and active life style.

This new concept is a revolutionary one because it solves the key biomechanics problem, as seen here: https://youtu.be/mtOGAFyEV8c.

The Kinetic Step biomechanical exoskeleton’s key benefits are:

• New Opportunities and Efficiency – It allows both able bodied and less able individuals to walk 2-3 times further, while using the same amount of energy
• Health – It gives elderly, sick, and injured people an opportunity to keep active, and enables fit individuals to walk even further
• Environmentally friendly
• Care – significantly reduces the stress put on leg joints and the spinal column daily
• Ergonomic – small size with versatile design of adaptable binding, which fits people with shoe size 5 to 13 (US), 34 to 46 (EU) and weight up to 160 kg

Kinetic Step does not use any external energy source to boost the individuals’ muscle strength. It is 40 times smaller in size and weight than other exoskeletons and its cost is 150 times lower, which makes it affordable to everyone. The project has been launched on the «Indiegogo» / crowdfunding platform, where customers can order their exoskeleton, https://www.indiegogo.com/projects/kineticstep/.

Official website: http://kineticstep.com/

Contact: kineticstep@gmail.com, +7-928-353-80-25

• New collaboration center to provide support from pre-clinical through full-scale production in a non-GMP environment
• Hands-on customer access to Merck’s product portfolio, technical expertise

SAO PAULO, Oct. 4, 2018 /PRNewswire/ — Merck, the vibrant science and technology company, today officially opened a state-of-the-art M Lab™ Collaboration Center in Brazil, serving the Latin America region. The center will provide Life Science customers with a shared, exploratory environment where they can closely collaborate with Merck scientists and engineers to solve their toughest challenges and accelerate development and production of new therapies.

“With a rapidly growing biopharmaceutical industry in Brazil and Latin America, and demand for novel and cost-effective therapies worldwide, there is a need for full end-to-end process development support,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science. “At our M Lab™ Collaboration Center, customers will benefit from Merck’s deep technical expertise to develop processes for manufacturing drugs faster, safer and more effectively than in the past.”

The 1,000-square meter lab facility includes non-GMP pilot and bench scale labs for customers to engage in process development support, troubleshooting, demonstrations and hands-on training. It is one of nine such centers around the world, each of which allows pharmaceutical manufacturers to explore new ways to increase productivity, improve processes and mitigate risks. Each year, more than 1,500 customers visit Merck’s M Lab™ Collaboration Centers, where they work alongside Merck’s team of experts and get access to sizing and simulation tools and methodologies as well as analytical and modeling support. Formal bioprocessing courses are also available, including traditional classroom-style training and interactive, hands-on sessions. Other M Lab™ Collaboration Center locations include China, Singapore, Japan, South Korea, India, France and the United States.

Merck opened its first customer-facing laboratory in 1995 in Massachusetts, USA. The global network has steadily grown over the years, not only to meet the training and process development needs of customers in local regions, but also to allow and ensure successful technology transfer between countries for global customers. In 2015, Merck began reimagining these labs as the M Lab™ Collaboration Centers with a focus on customers.

Follow Merck on Twitter @Merckgroup, on Facebook @merckgroup and on LinkedIn.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 53,000 employees work to further develop technologies that improve and enhance life — from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of 15.3 billion euro in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Photo – https://mma.prnewswire.com/media/752710/MilliporeSigma_M_Lab_Brazil.jpg

-Platinum Sponsor-

NEW YORK, Oct. 4, 2018 /PRNewswire/ — miR Scientific, LLC formerly known as miR Diagnostics (miR or the Company), a precision molecular bioscience company, today announces that Martin Tenniswood, Ph.D., Chief Scientific Officer presented at the 2018 World Urological Oncology Federation Conference to be held in Seoul, Korea on October 4, 2018 at 12:10PM Korea Time.    

“miR Scientific is very pleased to have presented and sponsored this renowned congregation of urological leadership,” said Sam Salman, Chief Executive Officer of miR Scientific. “We believe strongly in collaborating with the oncologists and urologists who are on the frontline of cancer treatment. We look forward to presenting the results of our latest research and having meaningful discussions about the latest breakthroughs on emerging biomarkers, with the aim of disrupting legacy diagnostic methodologies to rapidly and effectively improve urogenital cancer treatment.”

Presentation Time: 12:10PM Korea Time, October 4, 2018
Presentation Title: Urinary Micro RNAs and SNOs as a Prostate Cancer Biomarker Platform
Location: Seoul Dragon City

The World Urological Oncology Federation was formed by the global leadership of 19 societies of Urologic Oncology whose shared purpose is to provide a formal integration of members to address challenges facing worldwide oncology communities.  Laurence Klotz, M.D., FRCSC,CM, Chief Medical Officer of miR Scientific also serves as the conference chairman.

About miR Scientific, LLC

A subsidiary of NRS Health and Wellness GP LLC, miR Scientific is a precision molecular bioscience company that creates and delivers scalable breakthrough technologies for the provision of accessible diagnostic, prognostic, monitoring and companion products and services for large at-risk cancer populations.  miR’s pipeline of products includes the Prostate Cancer Sentinel Assay Test™, a urine-based liquid biopsy test with unprecedented accuracy that has the potential to save thousands of men from suffering possible severe side effects of unnecessary prostate cancer treatments. The Company was founded in 2014 as a commercial spin-out from the State of New York University at Albany’s Cancer Research Center and currently has operations in Rensselaer, New York City, Israel and Canada.  For more information, visit www.mirscientific.com.  

Forward-Looking Statements

This press release contains forward-looking statements, including with respect to the clinical development and prospects for commercialization of the Company’s product candidates, the impact and potential of the Company’s technology, and the expansion of the Company’s platform.  These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including delays or complications in clinical trials and attainment of regulatory approvals.  The events and circumstances discussed in such forward-looking statements may not occur, and the Company’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to the Company as of the date of this release.

Logo – https://mma.prnewswire.com/media/701096/miR_Scientific_Logo.jpg

HKSH doctors to join the first–in-market “AXA Signature Network” to provide a revolutionary medical service experience

HONG KONG, Oct. 3, 2018 /PRNewswire/ — AXA Hong Kong (“AXA”) and HKSH Medical Group (“HKSH”) entered into collaboration today (3 October 2018) under which HKSH will be the first and biggest partner of the market-first “AXA Signature Network” (“the Network”). Doctors from HKSH will provide quality and professional medical treatment and advice to AXA customers. As a long-term partner for its customers, AXA Hong Kong understands customer needs. The newly set up AXA Signature Network will be available in selected plans in the near future and will enable its customers to enjoy high-quality medical services, simplified procedures and a revolutionary medical services experience. It may also help to relieve the burden on the public medical system and the pressure on hospital beds.

“Rising healthcare costs have long been a concern for Hong Kong people. We strive to provide customers with adequate counselling and the most appropriate treatment when they need it with access to high-quality medical services. AXA shares the same beliefs with HKSH Medical Group. We are honoured to have them to join our AXA Signature Network as a founding member, and as the medical organisation with the largest number of participating medical professionals,” said Etienne Bouas-Laurent, Chief Executive Officer, AXA Hong Kong. “As a market-leading private hospital, HKSH Medical Group is recognised for its advanced medical technology and highly skilled medical professionals. We also have great confidence in their internal governance system, and believe our collaboration will bring the greatest benefits to patients. We aim to provide our customers with the most professional medical advice, simplest administrative procedures and the most comprehensive services.”

“The unprecedented collaboration in HKSH history represents a joint effort by HKSH Medical Group and AXA to put the patients first and foremost by broadening access to high-quality healthcare — top-ranking doctors in their respective fields, the most comprehensive array of advanced medical equipment and warm nursing care. The patient-centric approach demonstrated in the plan will help minimise patient anxiety by ensuring coverage and handling associated administrative tasks offline,” said Dr. Walton Li, Chief Executive Officer, HKSH Medical Group and Medical Superintendent of Hong Kong Sanatorium & Hospital.

“AXA Signature Network” is the first in the market, and will have 5 private hospitals with approximately 500 doctors in total participating in the Network, covering Hong Kong Island, Kowloon and the New Territories. The Network doctors will offer the best quality medical services in a simple, hassle-free and cashless way, thus enhancing the total customer experience. We will continue to develop and expand the “AXA Signature Network” and offer this in conjunction with our existing and new medical insurance and employee benefit plans. This not only gives more customers quality medical services in reputable private hospitals, but may also help to relieve the burden on the public medical system and the pressure on hospital beds,” said Yi-mien Koh, Managing Director of Health and Employee Benefits, AXA Hong Kong.

Comprehensive network with top-ranking doctors — HKSH as the first and biggest Network Partner

The first-in-the-market “AXA Signature Network” invited more than 130 doctors from HKSH to participate. As the first medical institution to join the “AXA Signature Network”, the specialist services from HKSH Medical Group are the most comprehensive in Hong Kong private hospitals, covering primary care to cutting-edge medical care.

“Over 130 HKSH specialists will be put on the ‘AXA Signature Network’ list, covering over 30 specialties. These doctors include our Honorary Consultants and we hope more will join in future,” Dr. Li added.

The plan will cover a number of common specialties, including Cardiology, Ophthalmology, Orthopaedics, Gastroenterology and Hepatology, Dermatology, Obstetrics & Gynaecology, Paediatrics, ENT Head and Neck Surgery, Oncology and Surgery.

“Other than the variety of specialities, service location is also important. HKSH Medical Group’s service locations under the Network will include our hospital campus in Happy Valley, all five sites for specialty services in the major business districts on Hong Kong Island and the new centre in Shau Kei Wan which will open in 2019. Patients using our services in different sites can be reassured that their electronic medical records will be accessible. The cooperation with AXA Hong Kong at this time reflects the trust and the confidence of the insurance industry towards HKSH’s clinical governance. HKSH will closely monitor clinical governance, maintain fee consistency and transparency to ensure the efficiency and quality of our medical services, as well as to protect patients’ rights,” said Dr. Joseph Chan, Chief Medical Officer, HKSH Medical Group cum Deputy Medical Superintendent of Hong Kong Sanatorium & Hospital.

Top expert to provide a second medical opinion[1]

In the face of critical illness, especially cancer, patients hope to seek the most appropriate medication and medical advice. AXA understands the needs of customers and believes that Hong Kong has the best medical professionals. The “AXA Signature Network” has invited the top local medical practitioners and authoritative experts from various specialities including university professors, academicians and experienced medical practitioners to offer a second opinion. With just one phone call, AXA will help to arrange one free meeting with an authoritative expert within ten working days after collecting a patient’s data. There will be no need to wait for a medical report from an overseas hospital, instead, the patient will be able to meet the local authoritative expert directly and obtain a second medical opinion in order to have the most appropriate medical treatment. There will be more products in the future to offer “AXA Signature Network”.

No pre-authorisation required and direct billing[2] to offer a simplified user experience

The “AXA Signature Network” will offer a simplified procedure, customers will only need to present their AXA medical cards[3] and personal identification document to the selected healthcare facilities in order to make an appointment with the medical practitioners within the Network. Without prior document submission and pre-authorisation, customers can focus on recovery and enjoy a cashless treatment experience as long as it is within the overall annual benefits limit[4] and the treatment is medically necessary.

“For the best medical care, we believe in 3Rs: ‘Right patient with the Right doctor for the Right procedure‘. It is through this that healthcare resources can be used most efficiently and effectively for the betterment of Hong Kong while ensuring better clinical outcomes,” Dr. Chan said.

ABOUT AXA HONG KONG

AXA Hong Kong, a member of the AXA Group, prides itself on serving over 1 million customers* in Hong Kong and Macau. Besides being one of the largest health protection providers in Hong Kong, it is also the #1 General Insurance provider^ and the #1 insurance brand worldwide for the ninth consecutive year^#.

AXA Hong Kong has a clear goal of ’empowering people to live a better life’. This is reflected in everything we do. AXA Hong Kong is one of the most diversified insurers providing a full range of coverage for individual and commercial customers. We offer all-round, integrated solutions across Life, Health and Property & Casualty to address all their insurance needs.

AXA Hong Kong leverages on Big Data and AI to transform the end-to-end customer experience, making insurance simpler and more personal. As an innovative insurer, we continue to drive innovation notably in health and protection, supporting customers in prevention, treatment and recovery.

We also believe it is our inherent responsibility to support the communities in which we operate. The AXA Foundation is our flagship corporate social responsibility programme covering all of our efforts in promoting health, education and community support to create a positive and lasting impact for Hong Kong.

About HKSH Medical Group

HKSH Medical Group, officially launched in September 2017, promotes public health and advanced medicine through a multi-faceted, coordinated approach in clinical services, medical education, scientific research and public health education. Members of the Group, including Hong Kong Sanatorium & Hospital, HKSH Healthcare and the soon-to-be commissioned HKSH Eastern Medical Centre, are dedicated to offering top-quality holistic care to patients, upholding the motto “Quality in Service, Excellence in Care”.

Hong Kong Sanatorium & Hospital, established in 1922, is one of the leading private hospitals in Hong Kong known for its high quality of patient care based on advanced knowledge, expertise and technology. With about 500 beds and more than 30 specialist centres, the Hospital is committed to ensuring clinical and health care excellence in a pleasant, comfortable and modern environment.

HKSH Healthcare comprises a network of medical centres, which aim at delivering state-of-the-art and patient-centred care in Hong Kong. It offers top-quality community care, primary care and specialty care at convenient locations throughout Hong Kong. HKSH Healthcare Medical Centre located at One Pacific Place in Admiralty, currently offers ophthalmology, refractive surgery, dental care, digestive medicine, endoscopy, day surgery, pain management, cardiology, dermatology, plastic and reconstructive surgery and skin laser services. Meanwhile, family medicine and primary care services are provided by HKSH Healthcare centres in Central, Taikoo, Island West and North Point. Oncology, neurology, rheumatology, and endocrine and diabetes services are also provided at our Central location while geriatric medicine services are available in both Central and Island West. Located in Tanner Hill, North Point, the Senior Citizen Wellness Centre is also now in service.

THIS PRESS RELEASE IS AVAILABLE ON AXA’S WEBSITE:  AXA.COM.HK

IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and AXA’s plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Please refer to Part 4 – “Risk factors and risk management” of AXA’s Document de Référence (Annual Report) for the year ended December 31, 2016, for a description of certain important factors, risks and uncertainties that may affect AXA’s business, and/or results of operations. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise.

Photo – https://photos.prnasia.com/prnh/20181003/2256183-1

ISNES, Belgium, Oct. 4, 2018 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced very encouraging preliminary results from a proof of concept study using its Nu.Q™ diagnostic test in veterinary medicine at the 10^th anniversary meeting of the Belgian Technology Mission at Texas A&M University. The meeting was sponsored in part by the Wallonia Export-Investment Agency (AWEX), a long-time supporter of Volition in Belgium.

The proof of concept study demonstrated that nucleosomes can be detected in dogs and, therefore, the potential to differentiate cancer from other conditions. Volition will now test its Nu.Q^™ platform in larger trials in veterinary medicine. Volition’s extensive intellectual property portfolio includes coverage of veterinary medicine applications.

While the veterinary market for cancer diagnostic testing is potentially large, Volition intends to do as much of this clinical trial work as possible through external collaborations thereby maintaining its internal focus on clinical research for human diseases. Volition has engaged an experienced consultant in the United States to define the business strategy and foster key relationships necessary to launch the commercialization process.

Volition plans to determine the performance of Nu.Q™ assays in larger trials in the most prevalent forms of canine malignancies in collaboration with Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical Sciences, Small Animal Clinical Sciences Department.

Dr. Heather Wilson-Robles commented, “The Texas A&M University College of Veterinary Medicine Oncology Department is excited for the opportunity to collaborate with Volition. Their innovative work in the early identification of cancer has the potential to significantly impact veterinary oncology as we know it.”

Dr. Jason Terrell, Chief Executive Officer of Volition America Inc., said, “We are fortunate to be a part of the unique relationship between the Wallon region of Belgium and Texas A&M University.  AWEX, Texas A&M, and the various affiliates have been extraordinarily helpful and supportive of our efforts. We’re confident this partnership will provide the framework to expedite the development and commercialization of our veterinary diagnostic platform. The U.S. is currently the largest veterinary market in the world and has a clearly defined regulatory pathway via the USDA, requiring fewer and smaller clinical studies than the FDA process for human diagnostics. This generally allows a much faster route to revenue for veterinary products as compared to human products.”

About Volition

Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

As cancer screening programs become more widespread, Volition’s products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. 

Volition intends to expand the application of its technology beyond cancer by exploring other disease applications. The company’s research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as it focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition’s website https://volitionrx.com/

or connect with us via:

Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition’s website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition’s website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media/Investor Contacts

Louise Day, Chief Marketing & Communications Officer
mediarelations@volitionrx.com
+44 (0)7557 774620

Scott Powell, Executive Vice President, Investor Relations
investorrelations@volitionrx.com 
+1 (646) 650 1351

Joseph Green, Edison Advisors
jgreen@edisongroup.com 
+1 (646) 653 7030

Safe Harbor Statement

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition’s bodily-fluid-based diagnostic tests as well as Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and/or other disease applications. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.Q™ and Hypergenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

View original content:http://www.prnewswire.com/news-releases/volitionrx-limited-to-expand-its-nuqtm-trials-to-veterinary-diagnostics-300724384.html

Source: Med X Change, Inc.

Source: Lifescan, Inc.

MIAMI, Oct. 3, 2018 /PRNewswire/ —

Leading companies and regulatory agencies adopt LifeSphere Intake and Triage, the principal application of LSMV suite   

ArisGlobal, a leading life sciences technology provider, announced the launch of LifeSphere MultiVigilance – the next-generation platform for individual case safety report (ICSR) intake powered by LifeSphere Nava – ArisGlobal’s cognitive computing engine. LifeSphere MultiVigilance is developed on a completely new, cutting-edge technology architecture designed for the cloud with the latest robotic automation and cognitive computing technologies including natural language processing (NLP) and machine learning to transform all pharmacovigilance (PV) activities.

LifeSphere MultiVigilance is also the first and only unified platform fully integrated with product quality complaints and medical information management, delivering a new dimension on compliance with seamless exchange of safety cases between these critical functions.

ArisGlobal has been partnering with leading pharmaceutical companies and regulatory agencies to develop the new platform. Together, ArisGlobal and its strategic partners focused on identifying business critical problems within safety case processing, and then identified innovative ways to solve these problems. Each of the PV platform’s automation functions were extensively tested during the development process by ArisGlobal’s PV and IT experts, with additional PV expertise provided by its partners.

LifeSphere Intake and Triage will transform into a fully functional safety system by Q3 2019, which Boehringer Ingelheim, one of ArisGlobal’s strategic automation partners, will implement. The new PV platform will replace legacy ARISg, and migration of its multi-tenant customer base to the new platform will occur over the next 12-18 months.

“LifeSphere MultiVigilance is the only production ready, cognitive computing enabled, case intake platform available today that can integrate with any type of safety system. This platform not only simplifies safety case processing but also leads to significant cost savings for all marketing authorization holders. We believe this platform is a game-changer for the industry, as our customers will achieve cost savings greater than 30% with higher data quality and compliance,” said Sankesh Abbhi, President and CEO, ArisGlobal. “No other platform can deliver this type of performance.”

Boehringer Ingelheim has been working closely with ArisGlobal on LifeSphere MultiVigilance. “We are extremely excited and optimistic about the quality and productivity gains that this technology will provide,” said Claudia Lehmann, Head of PV Operations, Boehringer Ingelheim. “We have seen how the platform’s advanced robotic automation and cognitive features will allow us to automate many of our key PV steps in the area of case processing, which are currently resource intensive.”

Additional Information 

For more on LifeSphere Intake and Triage: https://www.arisglobal.com/products/lifesphere-intake-and-triage/.

About ArisGlobal 

ArisGlobal is a visionary technology company that’s transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. The ArisGlobal LifeSphere® cognitive technology platform integrates machine-learning capabilities to automate the core functions of the product lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, our cognitive platform delivers actionable insights, boosts efficiency, ensures compliance, and lowers total cost of ownership through multi-tenancy.

Headquartered in the United States, ArisGlobal has regional offices in Europe, India and Japan. Visit arisglobal.com, or follow ArisGlobal on LinkedIn and Twitter.

CHRISTCHURCH, New Zealand, Oct. 3, 2018 /PRNewswire/ — ARANZ Medical now provides General Data Protection Regulation (GDPR) compliance with Microsoft’s Azure cloud hosting service, enabling the secure hosting of clinical trial data collected across multiple countries.

Data security and privacy has always been important for clinical trials, and now with the GDPR in place making sure that trial data collected across Europe meets these new rules is paramount.

Microsoft Azure is a GDPR compliant cloud computing service created by Microsoft for building, testing, deploying, and managing applications and services through a global network of Microsoft-managed data centers.

Bruce Davey, ARANZ Medical CEO says, “Being able to offer secure data hosting across countries with Microsoft Azure is a significant milestone for ARANZ Medical and Silhouette. Microsoft Azure also increases the capabilities of our clinical trial customers to monitor their systems and manage data in new and innovative ways.”

One of ARANZ Medical’s first European customers to benefit from the Microsoft Azure service is Promore Pharma AB who is running a Phase IIb clinical trial with the company’s product candidate LL-37 for treatment of venous leg ulcers. The trial will recruit 120 patients in Poland and Sweden.

ARANZ Medical has been a Microsoft Certified Development Partner for a number of years, utilizing a range of Microsoft development tools and support services, and now Microsoft Azure will enable growth for the company. Gabe Rijpma, Microsoft Senior Director Health Industry for Asia says, “I’m delighted to see ARANZ Medical taking this next step to build their presence in the EU after a long association with the company. Microsoft Azure will enable ARANZ Medical’s Silhouette solution to securely operate across multiple countries, which is often required for the kinds of specialized clinical trials that Silhouette is used for.”

ARANZ Medical’s Silhouette skin imaging and measuring solutions are a popular choice both for organizations undertaking clinical trials on skin and wound treatments and for clinical practice providers looking to improve their business and patient outcomes.  

About ARANZ Medical

ARANZ Medical Limited is a global medical device company focused on commercializing innovative, proprietary medical image-capture devices and recording, reporting and analysis software. The company’s systems are primarily used in the chronic wound market, and are well-suited to clinical trials and telemedicine applications. www.aranzmedical.com

View original content:http://www.prnewswire.com/news-releases/microsoft-partnership-opens-doors-for-aranz-medical-300723386.html